Moleculin Biotech Inc Dossier - Source-backed chat

Moleculin Biotech Inc

MBRXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.52

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $0.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $10.3M

Enterprise Value $3M

Shares Outstanding 19.5M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Moleculin Biotech is a late-stage clinical biopharmaceutical company whose investment thesis centers on its lead drug candidate, Annamycin. Annamycin is a next-generation anthracycline designed to avoid multidrug resistance and eliminate the severe cardiotoxicity common to conventional anthracyclines. The company is currently executing its pivotal Phase 2B/3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (R/R AML). With the 45th subject enrolled, the imminent mid-2026 unblinding of Part A data represents a major near-term catalyst. While the company faces significant going concern risks with cash projected to last only into Q3 2026, positive clinical data from the unblinding could dramatically de-risk the asset, facilitate necessary capital raises, and position the company as an attractive acquisition target.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$18.33

High · most bullish analyst$31.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The unblinded data fails to show a statistically significant efficacy advantage over the cytarabine control arm, or unexpected cardiotoxicity is detected. Given the company's limited cash runway (depleting in Q3 2026) and substantial doubt about its ability to continue as a going concern, the inability to raise capital leads to a severe down-round, trial suspension, or liquidation.

Base CaseCentral scenario

$4.0050%

The MIRACLE trial unblinding confirms a therapeutic benefit consistent with preliminary blinded data (composite complete remission rate around 40%) and maintains a clean cardiac safety profile. The company successfully raises the required $25 million through dilutive equity offerings or ATM sales, extending its cash runway into 2027 to support the transition to Part B of the trial.

Bull CaseUpside scenario

$22.0030%

The 45-subject unblinding in mid-2026 demonstrates strong efficacy (CRc > 40%) and confirms zero cardiotoxicity. This clinical success triggers a rapid, non-dilutive strategic partnership or a highly favorable equity financing round, fully funding the Phase 3 trial through 2028. Accelerated approval pathways are cleared with the FDA, leading to a rolling NDA submission by 2028.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Annamycin's unique mechanism of action avoids multidrug resistance and has demonstrated no detectable cardiotoxicity in clinical trials to date.
Imminent near-term catalyst with the unblinding of the first 45 subjects in the pivotal MIRACLE trial expected in mid-2026.
Fast Track and Orphan Drug designations from the FDA and EMA de-risk and accelerate the regulatory pathway toward a rolling NDA in 2028.

Key Investment Risks

Severe going concern risk with current cash resources of $10.3 million only sufficient to fund operations into Q3 2026.
High dependence on a single lead asset (Annamycin), making the company's valuation highly binary and sensitive to clinical trial outcomes.
Potential for substantial shareholder dilution as the company must raise approximately $25 million to fund operations into Q1 2027.

Thesis Invalidation Triggers

Failure of the unblinded 45-subject MIRACLE trial data to meet efficacy benchmarks or show a clear benefit over the control arm.
Detection of clinically significant cardiotoxicity in patients treated with Annamycin.
Inability to secure additional financing before the depletion of cash reserves in Q3 2026, leading to operational halt.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.